The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback